Lifeward (LFWD) EV/FCF: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:37:22.556Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:37:22.556Z.

Quote observation: 2026-10-06T15:30:15.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 10,595,554
Total debt · period ending 2026-06-30: 11,071,000
Cash · period ending 2026-06-30: 9,448,000
TTM free cash flow · period ending 2026-06-30: -17,087,000

FMP input reference: f6adff8253f4c85dc5eb0f5c76b7f284768243a99251a0912c87940a98678e1d

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

LFWD EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

LFWD Competitors' EV/FCF Ratio

LFWD

Lifeward Ltd.

Current

Market Cap

$10.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRZ

Polyrizon Ltd.

vs LFWD

Market Cap

$10.53M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MSLE

Satellos Bioscience Inc.

vs LFWD

Market Cap

$10.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNSY

Cerenome, Inc.

vs LFWD

Market Cap

$10.82M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CABR

Caring Brands, Inc.

vs LFWD

Market Cap

$10.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GDTC

CytoMed Therapeutics Limited

vs LFWD

Market Cap

$10.88M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LSTA

Lisata Therapeutics, Inc.

vs LFWD

Market Cap

$10.93M

EV/FCF Ratio

N/A

TTM Avg

5.79x

3Y Avg

5.79x

5Y Avg

5.79x

NMTC

NeuroOne Medical Technologies Corporation

vs LFWD

Market Cap

$10.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDCX

Medicus Pharma Ltd. Common Stock

vs LFWD

Market Cap

$10.07M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BIVI

BioVie Inc.

vs LFWD

Market Cap

$11.14M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Lifeward Ltd. (LFWD)	$10.60M	N/A	N/A	N/A	N/A
Polyrizon Ltd. (PLRZ)vs ›	$10.53M	N/A	N/A	N/A	N/A
Satellos Bioscience Inc. (MSLE)vs ›	$10.42M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$10.82M	N/A	N/A	N/A	N/A
Caring Brands, Inc. (CABR)vs ›	$10.36M	N/A	N/A	N/A	N/A
CytoMed Therapeutics Limited (GDTC)vs ›	$10.88M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$10.93M	N/A	5.79x	5.79x	5.79x
NeuroOne Medical Technologies Corporation (NMTC)vs ›	$10.18M	N/A	N/A	N/A	N/A
Medicus Pharma Ltd. Common Stock (MDCX)vs ›	$10.07M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.14M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

LFWD EV/FCF Ratio Metrics

LFWD Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics